The investor euphoria for Incyte’s experimental cancer drug is hard to rationalize – STAT
|
The investor euphoria for Incyte's experimental cancer drug is hard to rationalize
STAT Depending on who you ask, the cancer immunotherapy accounts for $10 billion to $12 billion of Incyte's current $27 billion market value. That's a huge bet on a single drug not yet approved. If epacadostat were a stand-alone company, it would be worth … |
